Company
Actavis LLC
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
5
3 still marketed
Novel approvals
0
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Cabazitaxel approved Mar 14, 2024
- Pemetrexed new use Nov 22, 2022
- Pemetrexed new use Nov 22, 2022
- Pemetrexed new use Nov 22, 2022
- Pemetrexed approved Aug 21, 2020
- Levoleucovorin Calcium approved OrphanSep 29, 2016
- Azacitidine approved Apr 29, 2016
- Docetaxel approved Apr 12, 2013
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (3)
Newest FDA action first.
- Azacitidine Azacitidine · 2016
- Docetaxel Docetaxel · 2013
- Pemetrexed Pemetrexed · 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.